Evidence map›Paper›PMID 34944558›Full record

ArticleBiomolecules2021

Bispecific Antibodies for IFN-β Delivery to ErbB2

Vladislav S Rybchenko, Anna A Panina, Teimur K Aliev, Olga N Solopova, Dmitry S Balabashin, Valery N Novoseletsky, Dmitry A Dolgikh, Petr G Sveshnikov, Mikhail P Kirpichnikov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Vladislav S RybchenkoDepartment of Bioengineering, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Anna A PaninaDepartment of Bioengineering, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Teimur K AlievDepartment of Chemistry, M.V. Lomonosov Moscow State University, 119234 Moscow, Russia.
Olga N SolopovaBlokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115478 Moscow, Russia.ORCID 0000-0002-5465-6094
Dmitry S BalabashinDepartment of Bioengineering, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Valery N NovoseletskyDepartment of Biology, M.V. Lomonosov Moscow State University, 119234 Moscow, Russia.
Dmitry A DolgikhDepartment of Bioengineering, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.ORCID 0000-0002-9880-7202
Petr G SveshnikovRussian Research Center for Molecular Diagnostics and Therapy, 117638 Moscow, Russia.
Mikhail P KirpichnikovDepartment of Bioengineering, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Lomonosov Moscow State University · RUInstitute of Bioorganic Chemistry · RURussian Research Center for Molecular Diagnostics and Therapy · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main aim of our work was to create a full-length bispecific antibody (BsAb) as a vehicle for the targeted delivery of interferon-beta (IFN-β) to ErbB2

Indexed as

Antibodies, BispecificAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingCell Line, TumorCell ProliferationCell SurvivalErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticHT29 CellsHumansImmunoglobulin Fc FragmentsInterferon-betaNeoplasmsTrastuzumabAntibodies, BispecificAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoglobulin Fc FragmentsInterferon-betaTrastuzumabbispecific antibodyErbB2IFN-β

Identifiers

PMID34944558
PMCPMC8699518
OpenAlexW4200242315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.